P. Lampertico

Long-term Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (Save-D)

Elisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, Thomas Reiberger et autres

it, at, fr, de, gr, gb, pt, us, se, ch (code pays fourni par la source)

Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 96 weeks: a retrospective multicenter european study (SAVE-D)

Maria Paola Anolli, Elisabetta Degasperi, Mathias Jachs, Thomas Reiberger et autres

it, at, fr, de, gr, us (code pays fourni par la source)

Baseline predictors of virological and biochemical responses in HDV compensated cirrhotic patients treated with Bulevirtide monotherapy (HEP4Di study)

E. Degasperi, M.P. Anolli, G. D'Offizi, M.R. Brunetto et autres

it (code pays fourni par la source)

Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

M. Iavarone, E. Alimenti, T. Tada, S. Shimose et autres

Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)

M.P. Anolli, E. Degasperi, G. D'Offizi, M.R. Brunetto et autres

it (code pays fourni par la source)

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …